The debate over CRISPR-based engineering is generally framed from an ethical and scientific perspective. The economic dimension is often overlooked.
There are a lot of things “physicians don’t want” — like having to adjust to a world where opioids prescribing must better monitored — but that doesn’t mean they need to be iced out of PDMP access.
Scott Gottlieb’s still nascent tenure as Food and Drud Administration commissioner has, to date, been defined by two terms not generally associated with the agency that regulates more than a third of the U.S. economy — predictability and imagination.
Last year, a week before Christmas in Kernville, Pa., 5-month-old Summer Chambers died in her crib from dehydration and starvation. Her parents — Jason Chambers, 27, and Chelsea Cardaro, 19 — had died about four days earlier from a non-abuse-deterrent opioid overdose.
In January, President Donald Trump said, “We have got to get our drug industry back.”
From Oregon to New York, Maryland to California and everyplace in between, states are proposing legislation to address pharmaceutical access, pricing and transparency.
The supporters of Oregon bill LC-1285 are calling for pharmaceutical price controls. So, let’s be honest, it doesn’t do that.
Patents save lives and enhance the value of medicines. As Abraham Lincoln said, “Patents add the fuel of interest to the passion of genius.”
Information never stops. We help you start your day by making sense of it all. Over 150,000 government and industry executives rely on Morning Consult to stay informed. Our original reporting and morning email briefings make it possible for you to know everything you need to know, every day, at the intersection of Wall Street and business strategy, policy and politics.